Patents Assigned to GlaxoSmithKline LLC
  • Chemical compounds
    Patent number: 8673948
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: August 19, 2011
    Date of Patent: March 18, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla, Andrew Larkin, Huiquiang Zhou, Eugene L. Stewart, Katherine Stetson, Darryl Lynn McDougald, Amarjit Sab Randhawa, John A. Ray
  • CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
    Publication number: 20140073679
    Abstract: An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 13, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Pingyun Y. CHEN, Jeffrey Gauling
  • Novel Method
    Publication number: 20140066516
    Abstract: The present invention is directed to a novel method for reducing intrapatient variability in pharmaceutically active agent which is suitably not absorbed in the stomach, such as paracetamol, containing formulations in patients having gastric dysmotility, or a method of improving analgesia in a diabetic patient, or improving absorption of an active agent is a patient with gastric dysmotility, which methods comprises administering orally to said patient in need thereof a pharmaceutical dosage form comprising a first active agent, calcium carbonate, at least one first binding agent, and at least one disintegrating agent as intragranular components in the form of a granulate, and as an extragranular component at least one hydrophilic colloid, an optionally a second binding agent, calcium carbonate, a super disintegrant, and a second active agent.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 6, 2014
    Applicant: GLAXOSMITHKLINE, LLC
    Inventors: Geoffrey Douglas Clarke, Timothy James Grattan, Ian Burnett
  • TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS
    Publication number: 20140066459
    Abstract: Tetrahydroquinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Application
    Filed: May 2, 2012
    Publication date: March 6, 2014
    Applicant: GlaxoSmithkline LLC
    Inventors: Dominique Amans, Emmanuel Hubert Demont, Katherine Louise Jones, Jonathan Thomas Seal, Ann Louise Walker
  • Sustained Release Paracetamol Formulations
    Publication number: 20140065213
    Abstract: The present invention is directed to twice daily sustained release pharmaceutical composition of paracetamol having an immediate release phase of paracetamol and a sustained release phase of paracetamol, said composition having unique and advantageous pharmacokinetic properties and a pharmaceutical composition comprising only a sustained release phase of paracetamol having unique and advantageous pharmacokinetic properties.
    Type: Application
    Filed: May 4, 2012
    Publication date: March 6, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: Carla Valenti Buan, Dongzhou Liu, Kanji Meghpara
  • NOVEL COMPOUNDS
    Publication number: 20140056928
    Abstract: Compounds of formula (I) and salts thereof: wherein R1 is n-C1-6alkyl or C1-2alkoxyC1-2alkyl-, R2 is halo, OH or C1-3alkyl, m is an integer having a value of 4, 5, 6 or 7, n is an integer having a value of 0, 1, 2 or 3, and p is an integer having a value of 0, 1 or 2, are inducers of human interferon. Compounds which induce human interferon may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and asthma, infectious diseases and cancer, and may also be useful as vaccine adjuvants.
    Type: Application
    Filed: August 22, 2013
    Publication date: February 27, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Diane Mary Coe, Stephen Allan Smith
  • CALCILYTIC COMPOUNDS
    Publication number: 20140057980
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • TRPV4 antagonists
    Patent number: 8658636
    Abstract: The present invention relates to quinoline analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: February 25, 2014
    Assignee: GlaxoSmithKline, LLC
    Inventors: Carl A. Brooks, Mui Cheung, Hilary S. Eidam, Ryan M. Fox, Mark A. Hilfiker, Eric S. Manas, Guosen Ye
  • FORMULATIONS WITH REDUCED VISCOSITY
    Publication number: 20140044727
    Abstract: The present invention is directed to a method for reducing the viscosity of a formulation containing acetate and a therapeutic protein and formulations made using the claimed method.
    Type: Application
    Filed: April 6, 2012
    Publication date: February 13, 2014
    Applicant: Glaxosmithkline LLC
    Inventors: Myrna A. Monck, Man Yi Wong, Kai Zhang
  • LYOPHILIZED FORMULATIONS
    Publication number: 20140044717
    Abstract: The invention is directed to a method for producing a polypeptide composition comprising: combining a polypeptide with a volatile additive to form a liquid mixture and lyophilizing the liquid mixture to obtain a lyophilized polypeptide composition.
    Type: Application
    Filed: February 9, 2012
    Publication date: February 13, 2014
    Applicant: GLAXOSMITHKLINE LLC
    Inventors: James Kranz, Joseph Rinella
  • 7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives
    Publication number: 20140045834
    Abstract: Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 13, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Emmanuel Hubert Demont, Katherine Louise Jones, Robert J. Watson
  • NOVEL PHARMACEUTICAL COMPOSITION
    Publication number: 20140037726
    Abstract: Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same.
    Type: Application
    Filed: October 2, 2013
    Publication date: February 6, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Douglas J. DeMARINI, Francisco HENRIQUEZ, Ngocdiep T. LE, Lihong WANG
  • Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors
    Publication number: 20140039006
    Abstract: Tetrahydroquinoline derivatives, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: April 19, 2012
    Publication date: February 6, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Dominique Amans, Emmanuel Hubert Demont, Darren Jason Mitchell, Robert J. Watson
  • 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)
    Publication number: 20140037580
    Abstract: An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicant: GlaxoSmithKline LLC
    Inventor: Stephen MOORE
  • CANCER TREATMENT METHOD
    Publication number: 20140038982
    Abstract: Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human.
    Type: Application
    Filed: May 31, 2013
    Publication date: February 6, 2014
    Applicant: GlaxoSmithKline LLC
    Inventor: Connie L. ERICKSON-MILLER
  • Antacid Tablet
    Publication number: 20140037759
    Abstract: Aspects of the present invention are directed to an oral antacid tablet comprising at least about 60% by weight directly compressible granulated calcium carbonate and an intense flavoring. The tablet may have a hardness of at least about 22 Strong-Cobb units and the tablet may have a mass of between about 500 mg and about 1,000 mg. Tablets of the present invention reduce or eliminate heartburn symptoms and also freshen breath.
    Type: Application
    Filed: January 31, 2013
    Publication date: February 6, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: Maria Mirabile, Sandip G. Shah
  • Benzene sulfonamide thiazole and oxazole compounds
    Patent number: 8642759
    Abstract: The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: February 4, 2014
    Assignee: GlaxoSmithKline LLC
    Inventor: Tara Renae Rheault
  • Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors
    Publication number: 20140031336
    Abstract: Tetrahydroquinoline compounds, pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Application
    Filed: April 19, 2012
    Publication date: January 30, 2014
    Applicant: Glaxosmithkline LLC
    Inventors: Dominique Amans, Emmanuel Hubert Demont, Darren Jason Mitchell, Jonathan Thomas Seal
  • Azaindazoles
    Patent number: 8637509
    Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: January 28, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Neil Johnson, Steven D. Knight, Louis LaFrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma, Dominic Suarez
  • Non-peptide thrombopoietin receptor agonist in the treatment of cancer and pre-cancerous syndromes
    Patent number: 8637563
    Abstract: Invented is a method of treating cancer or a pre-cancerous syndrome in a mammal, including a human, in need thereof which comprises the administration of an effective amount of a non-peptide thrombopoietin (TPO) receptor agonist to such mammal, suitably a human.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: January 28, 2014
    Assignee: GlaxoSmithKline LLC
    Inventor: Connie Erickson-Miller